Source: Eur Respir J, 55 (6) 1902383; 10.1183/13993003.02383-2019
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
Camus Nimmo, James Millard, Kayleen Brien, Sashen Moodley, Lucy van Dorp, Keeren Lutchminarain, Allison Wolf, Alison D. Grant, Francois Balloux, Alexander S. Pym, Nesri Padayatchi, Max O'Donnell. Bedaquiline resistance in drug-resistant tuberculosis HIV co-infected patients. Eur Respir J, 55 (6) 1902383; 10.1183/13993003.02383-2019

Member's Comments

No comment yet.

Related content which might interest you: Safety of bedaquiline for treatment of MDR/XDR tuberculosis in HIV co-infected patients Source: International Congress 2019 – Extra-pulmonary tuberculosis and comorbidities Year: 2019 Bedaquiline in treatment of TB/HIV co-infection patients with extremely-drug resistance of MBT Source: International Congress 2018 – Drug-resistant tuberculosis and the sequelae of pulmonary tuberculosis Year: 2018 Evaluation of the multidrug resistant TB in children with HIV infection Source: Eur Respir J 2004; 24: Suppl. 48, 439s Year: 2004 Linezolid for multidrug-resistant tuberculosis in HIV-infected and -uninfected patients Source: Eur Respir J 2015; 46: 271-274 Year: 2015 Multidrug-resistant TB in children with HIV infection Source: Annual Congress 2007 - Specific problems in caring for multidrug-resistant tuberculosis and tuberculosis/HIV cases Year: 2007 Experience in the use of Bedakville in the therapy of multidrug-resistant tuberculosis and HIV infection. Source: International Congress 2018 – Drug-resistant tuberculosis and the sequelae of pulmonary tuberculosis Year: 2018 Application of therapeutic pneumoperitoneum for multi-drug resistant cavitary TB in HIV – infected patients Source: Eur Respir J 2004; 24: Suppl. 48, 650s Year: 2004 The tuberculosis in patients with HIV and AIDS Source: Eur Respir J 2007; 30: Suppl. 51, 656s Year: 2007 The (in)significance of TB and COVID-19 co-infection Source: Eur Respir J, 56 (2) 2002105; 10.1183/13993003.02105-2020 Year: 2020 Multidrug-resistant tuberculosis (MDR-TB) and HIV co-infection in Romania Source: Annual Congress 2011 - Tuberculosis in immunocompromised hosts Year: 2011 On tuberculosis and COVID-19 co-infection Source: Eur Respir J, 56 (2) 2002328; 10.1183/13993003.02328-2020 Year: 2020 Multidrug resistant tuberculosis in non HIV patients Source: Annual Congress 2007 - Specific problems in caring for multidrug-resistant tuberculosis and tuberculosis/HIV cases Year: 2007 The peculiarities of drug susceptibility of M. tuberculosis isolated from patients with late-stage HIV infection Source: International Congress 2019 – Extra-pulmonary tuberculosis and comorbidities Year: 2019 Impact of extensive drug resistance on treatment outcomes in non-HIV infected adults with MDR-TB Source: Annual Congress 2007 - Multidrug-resistant tuberculosis and the emerging threat of extensively drug-resistant tuberculosis Year: 2007 Burden of the primary drug resistance of Mycobacterium tuberculosis in HIV-positive patients Source: International Congress 2019 – Extra-pulmonary tuberculosis and comorbidities Year: 2019 Extensively drug-resistant (XDR) pulmonary tuberculosis in HIV negative cases Source: Annual Congress 2008 - The challenge of multidrug-resistant tuberculosis Year: 2008 Bedaquiline in the treatment of patients with co-infection HIV/tuberculosis Source: International Congress 2018 – Drug-resistant tuberculosis and the sequelae of pulmonary tuberculosis Year: 2018 Treatment of drug-susceptible and drug-resistant tuberculosis Source: Eur Respir Monogr 2018; 82: 152-178 Year: 2018 Transthyretin in patients with pulmonary tuberculosis co-infected HIV. Source: Virtual Congress 2021 – Epidemiological aspects of tuberculosis Year: 2021 Primary drug resistance of mycobacterium tuberculosis in HIV-positive patients Source: International Congress 2016 – Non-tuberculous mycobacteria: HIV-TB co-infection and adenosine deaminase (ADA) Year: 2016